Angela Boland

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Topics

Metastatic Breast Cancer

Systematic Review

Health Promotion

Top Venues

PharmacoEconomics - open

Health technology assessment (Winchester, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Nigel Fleeman, Rachel Houten, Sarah Jane Nevitt, James Mahon, Sophie Beale, Angela Boland, Janette Greenhalgh, Katherine Edwards, Michelle Maden, Devarshi Bhattacharyya, Marty Chaplin, Joanne McEntee, Shien Chow, Tom Waddell
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England) 28 (49) (2024)
Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Rebecca Bresnahan, Rachel Houten, Janette Greenhalgh, Sarah Jane Nevitt, James Mahon, Sophie Beale, Angela Boland, Devarshi Bhattacharyya, Yenal Dundar, Joanne McEntee, Shreyans Gandhi, Nigel Fleeman, Marty Chaplin
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rebecca Bresnahan, Rui V Duarte, James Mahon, Sophie Beale, Marty Chaplin, Devarshi Bhattacharyya, Rachel Houten, Katherine Edwards, Sarah Jane Nevitt, Michelle Maden, Angela Boland
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation. Health technology assessment (Winchester, England) 27 (10) (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Juliet Hounsome, Gerlinde Pilkington, James Mahon, Angela Boland, Sophie Beale, Eleanor Kotas, Tara Renton, Rumona Dickson
Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation. Health technology assessment (Winchester, England) 24 (30) (2021)
Martin O'Flaherty, Ffion Lloyd-Williams, Simon Capewell, Angela Boland, Michelle Maden, Brendan Collins, Piotr Bandosz, Lirije Hyseni, Christodoulos Kypridemos
Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users. Health technology assessment (Winchester, England) 25 (35) (2021)
Nigel Fleeman, Rachel Houten, Marty Chaplin, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Rui V Duarte, Aditya Shenoy
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC cancer 19 (1) (2019)